According to KFF, a nonprofit health policy research, polling, and news organization, 43% of adults in the U.S. who have been diagnosed with diabetes have tried a GLP-1. However, of the respondents to this poll, 54% of those taking a GLP-1 said it was difficult to afford, thus making cost a continuous barrier to accessing this therapy.
Employers are uniquely positioned to provide access to medication-assisted weight care—and to do so without skyrocketing costs. Download this white paper to gain insights into GLP-1 alternatives and cost-containment strategies to effectively manage the utilization and costs of this class of drugs. You will also learn more about:
Download this white paper to gain insights into:
- Alternative anti-obesity medications (AOMs) and step therapy
- How to establish effective GLP-1 cost-control measures
- The importance of investing in weight care with a comprehensive approach
- How personalization unlocks a more effective path to weight loss for patients